trending Market Intelligence /marketintelligence/en/news-insights/trending/N93WWTIfoL7TuxoZIlc5LA2 content esgSubNav
In This List

UroGen Pharma starts rolling US FDA submission for bladder cancer drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


UroGen Pharma starts rolling US FDA submission for bladder cancer drug

Israel's UroGen Pharma Ltd. started the rolling submission of a new drug application to the U.S. Food and Drug Administration for cancer therapy UGN-101.

UGN-101, also known as mitomycin gel, is intended to treat low-grade upper tract urothelial cancer, a type of bladder cancer.

The drug's application is supported by data from a late-stage trial, called Olympus, topline results of which is expected in January 2019. The company anticipates to complete the rolling submission by mid-2019, and to receive approval within the same year.

UroGen Pharma said UGN-101 would provide a nonsurgical treatment option for urothelial cancer, potentially eliminating the need for repetitive surgical intervention and kidney removal.

The FDA has granted UGN-101 orphan-drug, fast-track and breakthrough-therapy designations.